目的 探討塞來昔布輔助治療對老年肺癌患者炎性介質(zhì)及肺功能的影響。方法 選取2014年1月—2016年6月在新鄉(xiāng)市中心醫(yī)院進行診治的130例老年非小細胞肺癌患者，按治療方法分為觀察組、對照組，各65例，對照組使用培美曲塞聯(lián)合順鉑進行化療，觀察組在對照組治療的基礎(chǔ)上給予塞來昔布輔助治療，兩組治療觀察3個月。比較兩組的療效及毒副反應(yīng)情況，比較兩組治療前后的炎癥因子、肺功能并隨訪到2017年12月，記錄患者生存期。結(jié)果 治療后觀察組與對照組的總有效率分別為72.31%和53.80%，觀察組顯著高于對照組，差異有統(tǒng)計學意義（P<0.05）。治療期間觀察組的皮膚反應(yīng)、骨髓抑制、消化道反應(yīng)等毒副反應(yīng)與對照組相比無顯著差異，所有毒副反應(yīng)對癥處理后好轉(zhuǎn)。觀察組與對照組治療后的血清IL-2與IL-6水平較治療前顯著降低，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；觀察組更明顯，組間差異有統(tǒng)計學意義（P<0.05）。治療后兩組的FEV1值較治療前顯著升高，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；觀察組明顯高于對照組，差異有統(tǒng)計學意義（P<0.05）。觀察組與對照組的中位生存期分別為（13.44±2.12）個月和（11.94±3.19）個月，KM法分析顯示觀察組高于對照組，差異有統(tǒng)計學意義（P<0.05）。結(jié)論 塞來昔布輔助治療老年肺癌患者能有效抑制炎性介質(zhì)的釋放，改善患者的肺功能，安全性好，從而有利于提高治療效果與延長患者的生存期。

Objective To investigate the effects of celecoxib on the inflammatory mediators and lung function in elderly patients with lung cancer.Methods Selected 130 elderly patients with non-small cell lung cancer in our hospital for diagnosis and treatment from January 2014 to June 2016. All the cases were divided into observation group and control group with 65 cases in each group accorded to the different treatment methods. The control group received pemetrexed plus cisplatin for chemotherapy, the observation group was given celecoxib therapy based on the treatment in control group, two groups were observed for 3 months.Results The total effective rates of the observation group and the control group after treatment was 72.31% and 53.8% respectively, and the observation group was significantly higher than that of the control group (P<0.05). There were no significant difference in skin reaction, bone marrow suppression and digestive tract reaction comapred between the observation group and the control group during the treatment period. All the side effects were improved after symptomatic treatment. The level of serum IL-2 and IL-6 in the observation group and the control group were significantly lower than that before the treatment (P<0.05), and the observation group was also significantly lower than the control group after treatment (P<0.05). After treatment, the FEV1 value of the two groups was significantly higher than that before the treatment (P<0.05), and the FEV1 value of the observation group was significantly higher than that of the control group after treatment (P<0.05). The median survival time of the observation group and the control group were (13.44 ±2.12) months and (11.94 ±3.19) months respectively, KM analysis showed that the observation group was higher than the control group (P<0.05).Conclusions The celecoxib in the treatment of elderly patients with lung cancer can effectively inhibit the release of inflammatory mediators, improve the lung function and safety of patients, thereby improve the therapeutic effect and prolong the survival time of patients.